Pacific Biosciences of California, Inc.
corporate_fare Company Profile
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 28 items for PACB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 8 rated 8 or above. Recent SEC coverage for PACB spans 424B5, 8-K, 10-Q, DEFA14A.
Recent high-impact activity:
- PacBio Launches $100M At-The-Market Stock Program Via Allen & Company
- PacBio Adds GeneDx, TychoBio Deals Alongside Q3 Revenue Growth and CFO Handoff
- CFO Exits Days After Q3 Loss as PacBio Turnaround Stumbles
- PacBio Q3 Loss Widens Marginally as CFO Exits; Guidance Narrowed to $155M-$160M
- PacBio Posts 12-Cent Quarterly Loss as Turnaround Pressure Mounts
Financial Snapshot
Short Interest & Short Volume
4.14 days to coverFINRA reported short interest of 53,681,529 shares in PACB as of the October 30, 2026 settlement, a 14.4% increase from the prior period — about 4.1 days to cover at its recent average daily volume. On November 20, 2026, 60.8% of PACB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for PACB, detected from its recent SEC filings · based on capital-structure filings through 2026-11-10.
New $100M At-The-Market Program · Dilution If Fully Drawn
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →